Synthetic Biologics appoints interim CEO to permanent role
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Synthetic Biologics Inc. said it named Steven Shallcross CEO.
Shallcross, who had been serving as interim CEO, will also continue as the company's CFO. He was also appointed as a director of the company.
Rockville, Md.-based Synthetic Biologics develops therapeutics designed to preserve the human microbiome.
